Amide local anesthetic (high-potency topical)

Plain-language summaryIntrigue 52 / 100

Dibucaine (cinchocaine, Nupercaine) is a quinoline-based amide local anesthetic synthesized at Ciba in 1929. It is the most potent local anesthetic in the amide class on a milligram basis (roughly 15-fold the potency of lidocaine for infiltration), but the high potency comes paired with high systemic toxicity that restricts modern use to topical preparations like hemorrhoidal creams. The historical use in spinal anesthesia was extensive in the early-to-mid 20th century but has been displaced by safer agents. The compound has an interesting second life as a clinical laboratory test: the dibucaine number measures plasma butyrylcholinesterase activity through the relative inhibition of cholinesterase by dibucaine. Normal individuals show 80 percent inhibition; atypical heterozygotes 40 to 60 percent; atypical homozygotes 16 to 20 percent. The number predicts succinylcholine and mivacurium duration in patients with butyrylcholinesterase variants. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

29/100

A 1929 anesthetic displaced by safer alternatives, surviving only as the cholinesterase typing reference standard

Look, dibucaine is old. Synthesized by Karl Miescher at Ciba in 1929, it predates essentially every compound in any modern research library worth talking about. The mechanism is voltage-gated sodium channel block with state-dependent kinetics. That’s it. That’s the whole story. There’s no dual-target angle, no allosteric wrinkle, no novel receptor biology. The quinoline ring makes it structurally distinctive on paper, but that structural distinction hasn’t generated any interesting downstream pharmacology that a researcher in 2025 would care about.

The clinical arc is also telling. Dibucaine was once used for spinal anesthesia under the Nupercaine trade name, where its extreme potency (roughly 15-fold lidocaine on a milligram basis for infiltration block) was considered useful. That use is gone. The same potency that made it attractive in spinal preparations is paired with high systemic toxicity, and when bupivacaine, levobupivacaine, and ropivacaine arrived, dibucaine spinal was quietly shelved. Modern indications are topical only, hemorrhoidal creams and ENT applications. That’s a clinical trajectory going the wrong direction for a research audience.

What keeps dibucaine from scoring at absolute floor is the dibucaine number. Kalow and Genest established in the early 1950s that dibucaine selectively inhibits wild-type plasma butyrylcholinesterase more strongly than atypical variants, and the percent inhibition (normal: roughly 80 percent; atypical homozygote: roughly 16-20 percent) became the diagnostic reference for succinylcholine and mivacurium duration phenotyping. That’s genuinely useful bench chemistry. If you’re working on pseudocholinesterase biology, BChE variant pharmacogenomics, or the neuromuscular pharmacology of depolarizing blockers, dibucaine is still the probe you reach for. We don’t want to dismiss that. But it is a very narrow lane, and the test itself is a 70-year-old assay. It’s not a frontier.

Honestly, the evidence quality axis is the one place dibucaine looks decent by the numbers, because decades of use in surgery and a well-validated clinical assay produce a real evidence base. But that evidence is entirely historical and doesn’t point at any new direction worth pursuing. There’s no exciting preclinical pipeline, no emerging indication, no mechanistic reinterpretation that a serious investigator would prioritize. The translational arrow points backward, not forward.

We’d include dibucaine in the library for completeness and for researchers specifically working on cholinesterase phenotyping. For anyone else, theres little reason to give it bench time over compounds with live research trajectories. It’s a reference standard masquerading as a research compound.

Novelty: 8
Mechanism promise: 12
In-category differentiation: 28
Evidence quality: 62
Translational signal: 42
Research bench value: 38

Rationale Dibucaine scores low across novelty and mechanism because it is a 96-year-old textbook Na+ channel blocker with no new pharmacological story, and high systemic toxicity removed it from active clinical anesthesia decades ago. Its one surviving research-relevant role is as the reference inhibitor for butyrylcholinesterase phenotyping (the dibucaine number), which gives it narrow but real bench utility and lifts differentiation slightly above floor.

Amide local anesthetic (high-potency, topical)

A quinoline-based amide local anesthetic with the highest potency in the class, used principally in topical preparations and as the historical reference for cholinesterase typing.

Abstract

Dibucaine (cinchocaine; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide; CAS 85-79-0; molecular formula C20H29N3O2; molecular weight 343.46) is a quinoline-based amide local anesthetic synthesized by Karl Miescher at Ciba in 1929 (Nupercaine, Cinchocaine, Sovcaine). The compound is structurally distinct in carrying a quinoline ring and a butyloxy substituent rather than the dimethylphenyl ring of lidocaine and pipecoloxylidide-family agents. Dibucaine is the most potent local anesthetic in the amide class on a milligram basis (approximately 15-fold the potency of lidocaine for infiltration block), producing intense and prolonged sodium channel block; the high potency is paired with high systemic toxicity that restricts modern clinical use to topical preparations. The historical use in spinal anesthesia (Nupercaine spinal) was extensive in the early-to-mid 20th century but has been displaced by safer agents (bupivacaine, levobupivacaine, ropivacaine). Modern indications are topical: hemorrhoidal preparations (combined with hydrocortisone in commercial products), topical anesthesia of intact skin and mucous membranes, and ENT applications. Mechanism is the standard voltage-gated sodium channel block with state-dependent kinetics. The dibucaine number is a clinical laboratory parameter measuring plasma butyrylcholinesterase activity through the relative inhibition of cholinesterase by dibucaine: normal individuals show 80 percent inhibition, atypical heterozygotes 40 to 60 percent, atypical homozygotes 16 to 20 percent. The dibucaine number predicts succinylcholine and mivacurium duration in patients with butyrylcholinesterase variants and remains a clinically used diagnostic test.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1318Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Amide local anesthetic (high-potency topical)

Dibucaine

Abstract

Read the full monograph